{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Large-Cell+Neuroendocrine+Carcinoma&page=2",
    "query": {
      "condition": "Large-Cell Neuroendocrine Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Large-Cell+Neuroendocrine+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T03:15:03.689Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05680922",
      "title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer Extensive Stage",
        "Large Cell Neuroendocrine Carcinoma of the Lung"
      ],
      "interventions": [
        {
          "name": "LB2102",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Legend Biotech USA Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2023-07-26",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Lexington, Kentucky • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05680922"
    },
    {
      "nct_id": "NCT04010357",
      "title": "Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Large Cell Neuroendocrine Carcinoma of the Lung",
        "Extrapulmonary Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib,",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-01-13",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04010357"
    },
    {
      "nct_id": "NCT07707895",
      "title": "A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Large Cell Neuroendocrine Lung Carcinoma",
        "Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology",
        "Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology"
      ],
      "interventions": [
        {
          "name": "Obrixtamig",
          "type": "DRUG"
        },
        {
          "name": "ZL-1310",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-08-26",
      "completion_date": "2030-04-26",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Lexington, Kentucky",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07707895"
    },
    {
      "nct_id": "NCT00445965",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Intraocular Melanoma",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        },
        {
          "name": "131I-3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 78,
      "start_date": "2006-01",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445965"
    },
    {
      "nct_id": "NCT00314925",
      "title": "Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoid",
        "Neuroendocrine"
      ],
      "interventions": [
        {
          "name": "Seneca Valley Virus (biological agent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neotropix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2006-04",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2010-02-25",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 10,
      "location_summary": "Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Kettering",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00314925"
    },
    {
      "nct_id": "NCT02709889",
      "title": "Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma",
        "Medullary Thyroid Cancer",
        "Glioblastoma",
        "Large-Cell Neuroendocrine Carcinoma",
        "Neuroendocrine Prostate Cancer",
        "High Grade Gastroenteropancreatic Neuroendocrine Carcinoma",
        "Other Neuroendocrine Carcinoma",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Rovalpituzumab tesirine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-09-23",
      "completion_date": "2019-08-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709889"
    },
    {
      "nct_id": "NCT04772989",
      "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Melanoma",
        "Cervical Cancer",
        "Multiple Myeloma",
        "Lymphoma, Non-Hodgkin",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "AB308",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2021-03-19",
      "completion_date": "2025-08-25",
      "has_results": false,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04772989"
    },
    {
      "nct_id": "NCT03110978",
      "title": "Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Atypical Carcinoid Tumor",
        "Lung Neuroendocrine Neoplasm",
        "Lung Non-Small Cell Squamous Carcinoma",
        "Minimally Invasive Lung Adenocarcinoma",
        "Neuroendocrine Carcinoma",
        "Recurrent Lung Adenocarcinoma",
        "Recurrent Lung Large Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage I Lung Cancer AJCC v8",
        "Stage IA1 Lung Cancer AJCC v8",
        "Stage IA2 Lung Cancer AJCC v8",
        "Stage IA3 Lung Cancer AJCC v8",
        "Stage IB Lung Cancer AJCC v8",
        "Stage IIA Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2017-06-26",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 3,
      "location_summary": "Conroe, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110978"
    },
    {
      "nct_id": "NCT00499733",
      "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cryoablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 19,
      "start_date": "2007-06",
      "completion_date": "2013-01-09",
      "has_results": false,
      "last_update_posted_date": "2019-01-18",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499733"
    },
    {
      "nct_id": "NCT07278479",
      "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Large Cell Neuroendocrine Carcinoma",
        "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",
        "Small Cell Lung Cancer (SCLC)",
        "Gastroenteropancreatic NEC (GEP NEC)",
        "NEC of the Bladder",
        "Other DLL3 Expressing epNEC"
      ],
      "interventions": [
        {
          "name": "[212Pb]Pb-MP0712",
          "type": "DRUG"
        },
        {
          "name": "[203Pb]Pb-MP0712",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Molecular Partners AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-05-18",
      "completion_date": "2032-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-07-23T03:15:03.689Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Glen Burnie, Maryland • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07278479"
    }
  ]
}